<DOC>
	<DOCNO>NCT00091598</DOCNO>
	<brief_summary>The primary objective determine effect ambrisentan exercise capacity subject PAH .</brief_summary>
	<brief_title>ARIES - Ambrisentan Patients With Moderate Severe Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description>ARIES-1 North America Australia ARIES-2 Western Eastern Europe , South America Israel Subjects randomize study receive one two dos ambrisentan placebo . Inclusion base specify WHO functional classification . Rather , subject WHO Class I-IV symptom eligible 6-minute walk distance 150-450 meter meet study-specified hemodynamic criterion . Subjects anorexigen HIV infection relate PAH eligible subject congenital heart disease pediatric subject exclude . The study require historical cardiac catheterization diagnostic procedure .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Diagnosis idiopathic PAH ( formally know PPH ) , PAH associate collagen vascular disease , anorexigen use , HIV infection ; Historical cardiac catheterization follow hemodynamic criterion : Mean pulmonary artery pressure great equal 25 mmHg ; Pulmonary vascular resistance great 3 mmHg/L/min ; Pulmonary capillary wedge pressure leave ventricular end diastolic pressure le 15 mmHg ; 6minute walk distance least 150 meter , 450 meter ; Total lung capacity great equal 70 % FEV1 great equal 65 % predict normal ; Portopulmonary hypertension ; Subjects PAH due associate coronary artery disease , leave heart disease , interstitial lung disease , chronic obstructive pulmonary disease , venoocclusive disease , chronic thromboembolic disease , sleep apnea ; Bosentan ( Tracleer® ) , sildenafil ( Viagra® ) , chronic prostanoid therapy within 4 week screen ; Serum ALT AST lab value great 1.5 time upper limit normal ; Contraindication treatment endothelin receptor antagonist ; Subject cardiovascular , hepatic , renal , hematologic , gastrointestinal , immunologic , endocrine , metabolic , central nervous system disease may adversely affect safety subject ; Participation clinical study involve another investigational drug within 4 week screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
</DOC>